Skip to content

Study · Case report or series · n = 1 · 2023

1 result

First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.

Saffati G, Naeem T, Kaaki B, Khera M

Sexual medicine1 Dec 2023Cited by 1 (Europe PMC)

PMID38222292 (opens in a new tab)PMCIDPMC10786674 (opens in a new tab)DOI10.1093/sexmed/qfad066 (opens in a new tab)PepBankPUB-38222292
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

IntroductionAnorgasmia is a poorly understood phenomenon defined as either a lifelong or acquired consistent inability to achieve ejaculation. Despite the prevalence of anorgasmia, there is currently no established treatment for the condition.AimsTo report a unique case of a patient with lifelong anorgasmia who was able to achieve his first orgasm with off-label use of flibanserin.MethodsThe present case study relies on the patient's self-report and a review of the relevant literature. The patient provided written informed consent.ResultsA 28-year-old male presented to our office with complaints of lifelong anorgasmia, without any signs of erectile dysfunction. He reported good libido and energy levels and denied any urinary symptoms or history of depression. The patient failed medical management with numerous off-label medications, including bupropion and bremelanotide. Despite having received 4 or 5 sex therapy sessions over 3 months, the patient reported that this treatment approach was not effective. Off-label use of flibanserin was then initiated, and after 28 to 32 doses over 4 weeks, he achieved his first orgasm. Notably, the patient experienced nocturia and insomnia. The follow-up International Index of Erectile Function score marginally improved by 2 points without any improvement in the overall satisfaction subdomain.ConclusionThis case highlights the challenges of managing anorgasmia and anejaculation in a young male patient. A stepwise approach involving pharmacotherapy and sex therapy was not successful. However, the off-label use of flibanserin ultimately resulted in the patient achieving his first orgasm, albeit with some side effects. Further studies are needed to evaluate the efficacy and safety of flibanserin in men for this indication.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 28-year-old man with lifelong anorgasmia, off-label bremelanotide did not resolve the condition.

    In plain wordsIn one man with lifelong anorgasmia, off-label bremelanotide did not work.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeResponse of lifelong anorgasmia to bremelanotide
    Study

    n = 1

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient failed medical management with numerous off-label medications, including bupropion and bremelanotide.
    1 context sentence
    Summary · context
    A 28-year-old male presented to our office with complaints of lifelong anorgasmia, without any signs of erectile dysfunction.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.